Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28125379 | 0.90 | PSMB8 (0.54) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6479111 | 0.88 | PSMB8 (0.51) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6479909 | 0.88 | PSMB8 (0.51) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6622094 | 0.88 | TP53 (0.60) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL28125380 | 0.88 | KDM4E (0.46) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1877753 | 0.84 | PIM1 (0.45) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL28044374 | 0.83 | PIM1 (0.56) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL28375846 | 0.83 | PSMB8 (0.52) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15349478 | 0.82 | PSMB8 (0.47) | PSMB8NPC1RAB9AMEN1KMT2A | |
| SCHEMBL24138422 | 0.82 | PIM1 (0.51) | NPC1RAB9AMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | PSMB8 3719/4885NPC1 284/4885RAB9A 1279/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | PSMB8 3719/4885NPC1 284/4885RAB9A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.